AEON Biopharma, Inc. (AEON)

AEON Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	-	-	-	-	2.52
Revenue	-	-	-	-	2.52
Revenue Growth (YoY)	-	-	-	-	-24.99%
Gross Profit	-	-	-	-	2.52
Selling, General & Admin	13.64	19.79	13.68	11.15	11.59
Research & Development	14.18	33.05	34.75	25.73	7.32
Operating Expenses	27.82	52.84	48.43	36.88	18.91
Operating Income	-27.82	-52.84	-48.43	-36.88	-16.39
Interest Expense	-	-	-	-	-0.02
Other Non Operating Income (Expenses)	-34.29	-17.19	0.29	-0.14	-0.12
EBT Excluding Unusual Items	-62.12	-70.02	-48.14	-37.02	-16.52
Gain (Loss) on Sale of Investments	-	-	-	-	0.35
Legal Settlements	-	-	-	-28.97	-
Other Unusual Items	104.12	33.39	-4.42	10.35	-16.74
Pretax Income	42.01	-384.63	-52.56	-55.64	-32.91
Earnings From Continuing Operations	42.01	-384.63	-52.56	-55.64	-32.91
Net Income	42.01	-384.63	-52.56	-55.64	-32.91
Preferred Dividends & Other Adjustments	-	-	-	-	17.26
Net Income to Common	42.01	-384.63	-52.56	-55.64	-50.17
Shares Outstanding (Basic)	1	77	2	2	0
Shares Outstanding (Diluted)	1	77	2	2	0
Shares Change (YoY)	-99.25%	3896.62%	9.98%	1813.85%	-0.74%
EPS (Basic)	77.74	-4.99	-27.25	-31.73	-547.60
EPS (Diluted)	72.93	-4.99	-27.25	-31.73	-547.60
Free Cash Flow	-20.29	-47.83	-35.89	-28.6	-9.46
Free Cash Flow Per Share	-35.23	-0.62	-18.61	-16.31	-103.26
Gross Margin	-	-	-	-	100.00%
Operating Margin	-	-	-	-	-650.83%
Profit Margin	-	-	-	-	-1992.53%
Free Cash Flow Margin	-	-	-	-	-375.74%
EBITDA	-27.73	-52.74	-48.36	-36.88	-15.51
D&A For EBITDA	0.1	0.1	0.07	0	0.88
EBIT	-27.82	-52.84	-48.43	-36.88	-16.39

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q